ABBOTT PARK, Ill., Nov. 11 /PRNewswire-FirstCall/ -- Several data presentations from Abbott’s portfolio of investigational neuroscience compounds will be presented at this week’s Neuroscience 2005 meeting taking place in Washington D.C. Neuroscience is the annual meeting of the Society for Neuroscience.
Abbott will present new data from three promising areas of neuroscience research. Alzheimer’s disease, schizophrenia and pain management present areas of significant unmet medical need for which current treatment options are insufficient. Abbott has a number of programs in each of these areas, focusing on novel approaches that may hold promise for the development of new therapies for patients.
Following is a list of select data presentations.
Alzheimer’s disease
Data will be presented on the discovery of a new form of amyloid Beta-peptide that Abbott scientists have shown to be present in the brains of patients with Alzheimer’s, and which selectively bind to nerve cells in the brain, thereby disrupting learning and memory. These findings may open the door to new therapeutic approaches.
-- “Amyloid 1-42 Oligomers: A New Stable Soluble A Beta Form with Distinct Physico-chemical Properties, Neuronal Binding and Pathogenic Character.” [Poster session, Poster #893.7: Embargoed until Wednesday, Nov. 16 at 10 a.m. ET; 10 - 11 a.m. ET, Hall A, Lower Level, Row PP, Board 30] Schizophrenia
Abbott has taken a unique approach to schizophrenia research, targeting efforts on finding compounds that selectively bind to the dopamine D3 receptor to target the positive, negative and cognitive symptoms of the disease while showing favorable tolerability. Data being presented shares the results of several preclinical studies.
-- “ABT-127, a New Selective Dopamine D3 Receptor Antagonist: Binding and Functional Properties In Vitro.” [Poster Session, Poster # 913.18: Embargoed until Wednesday, Nov. 16 at 10 a.m. ET; 10 - 11 a.m. ET, Hall A, Lower Level, Row UU, Board 76] -- “ABT-127, a New Selective Dopamine D3 Receptor Antagonist: Behavioral Pharmacology Studies.” [Poster Session, Poster #913.20: Embargoed until Wednesday, Nov. 16 at 11 a.m. ET; 11 a.m. - 12 p.m. ET, Hall A, Lower Level, Row UU, Board 78] -- “ABT-127, a New Selective Dopamine D3 Receptor Antagonist: Neurochemical and Electrophysiological Studies In Vivo.” [Poster Session, Poster #913.19: Embargoed until Wednesday, Nov. 16 at 10 a.m. ET; 10 - 11 a.m. ET, Hall A, Lower Level, Row UU, Board 77] Pain Management
For several years, capsaicin, the substance that occurs naturally in chili peppers causing a burning sensation in the mouth, has been used topically to treat pain. Abbott scientists are targeting the receptor that mediates the initial pain response to capsaicin. Compounds have been identified which block this receptor and display efficacy comparable to opioids in preclinical pain models. Data being presented will highlight these preclinical findings.
-- “The Central Nervous System Plays a Critical Role in Broad-Spectrum Analgesia of TRPV1 Antagonists.” [Poster Session, Poster #172.12: Embargoed until Sunday, Nov. 13 at 11 a.m. ET; 11 a.m. - 12 p.m. ET, Hall B, Lower Level, Row Y, Board 18] -- “The Novel and Potent TRPV1 Antagonist, A-784168, is a Broad-Spectrum Analgesic in Preclinical Pain Models.” [Poster Session, Poster #172.11: Embargoed until Sunday, Nov. 13 at 10 a.m. ET; 10 - 11 a.m. ET, Hall B, Lower Level, Row Y, Board 17]
Abbott is committed to neuroscience and the research and development of new treatments for neurological disorders. Abbott’s neuroscience research focuses on central nervous system (CNS) disorders as well as pain management targeting a variety of different pathways and novel mechanisms, using both small-molecule and biologics-based approaches. Abbott’s CNS drug discovery scientists in the United States and Europe are pursuing innovative treatments for a variety of CNS disorders, including, schizophrenia, depression, attentional and cognitive disorders and neurodegeneration. In pain management, Abbott scientists are working to discover safer, more effective therapies across the spectrum of pain, from acute to chronic, moderate to severe, to provide patients with additional treatment options.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 60,000 people and markets its products in more than 130 countries.
Abbott’s news releases and other information are available on the company’s Web site at http://www.abbott.com .
Abbott
CONTACT: Elizabeth Hoff, +1-847-935-4236, or Catherine Bryan,+1-847-936-6722, both of Abbott
Web site: http://www.abbott.com/
Company News On-Call: http://www.prnewswire.com/comp/110328.html/
